| Identification | Back Directory | [Name]
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide | [CAS]
345627-80-7 | [Synonyms]
CS-202
SNS-032
BMS-387032
BMS-3870032
SNS-032, >=99%
SNS0032(BMS-387032)
SNS-032, 98.5%, a selective CDK2 inhibitor
BMS-387032; SNS 032; SNS032; BMS 387032; BMS387032
1-diMethylethyl)-2-oxazolyl]Methyl]thio]-2-thiazolyl]-
SNS 032; SNS032; SNS-032; BMS387032; BMS 387032; BMS-387032
N-[5-[(5-tert-Butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thia...
N-(5-((5-Tert-Butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide
N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamid
4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide(BMS-3870032)
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide USP/EP/BP
BMS-3870032
N-[5-[(5-tert-Butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
N-[5-[(5-tert-Butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide SNS-032 (BMS-387032) | [Molecular Formula]
C17H24N4O2S2 | [MDL Number]
MFCD09833875 | [MOL File]
345627-80-7.mol | [Molecular Weight]
380.53 |
| Chemical Properties | Back Directory | [Melting point ]
171-173 °C | [density ]
1.28±0.1 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2–8 °C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.33±0.70(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. SNS-032 is an ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively.1 It is selective for these kinases and displays no additional activity against a panel of 190 kinases (IC50s = >1,000 nM).1 SNS-032 can block the cell cycle, inhibit transcription, and induce apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM.2 This compound has been shown to induce apoptosis by inhibiting the transcription of the anti-apoptotic proteins, Mcl-1 and XIAP.3 | [Chemical Properties]
Off-White Solid | [Uses]
SNS 032 is a selective inhibitor of Cyclin-dependent Kinase (CDK) 2,7, and 9. | [Definition]
ChEBI: N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide is a secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties. It has a role as an apoptosis inducer, an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor and an angiogenesis inhibitor. It is a piperidinecarboxamide, a member of 1,3-oxazoles, a member of 1,3-thiazoles, an organic sulfide and a secondary carboxamide. | [storage]
Store at -20°C | [References]
[1]. tong w.g., chen r., plunkett w., et al. phase i and pharmacologic study of sns-032, a potent and selective cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. journal of clinical oncology, 2010, 28(18):3015- 3022.
[2]. chipumuro e., marco e., christensen c.l., et al. cdk7 inhibition suppresses super-enhancer-linked oncogenic transcription in mycn-driven cancer. cell, 2014, 159:1-14.
[3]. meng h., jin y.m., liu h., et al. sns-032 inhibits mtorc1/mtorc2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against akt. journal of hematology & oncology, 2013, 6:18.
[4]. chen r., wierda w.g., chubb s., et al. mechanism of action of sns032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. blood, 2009, 113(19):4637-4645. |
|
|